+

WO1999059618A1 - Acrp30r1l, homologue de acrp30 (proteine associee a un complement de l'adipocyte 30 kd) - Google Patents

Acrp30r1l, homologue de acrp30 (proteine associee a un complement de l'adipocyte 30 kd) Download PDF

Info

Publication number
WO1999059618A1
WO1999059618A1 PCT/US1999/010822 US9910822W WO9959618A1 WO 1999059618 A1 WO1999059618 A1 WO 1999059618A1 US 9910822 W US9910822 W US 9910822W WO 9959618 A1 WO9959618 A1 WO 9959618A1
Authority
WO
WIPO (PCT)
Prior art keywords
polypeptide
seq
identity
amino acid
polynucleotide
Prior art date
Application number
PCT/US1999/010822
Other languages
English (en)
Inventor
Preston Hensley
Xiaotong Li
Erding Hu
Randall Forrest Smith
Yuan Zhu
Original Assignee
Smithkline Beecham Corporation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Smithkline Beecham Corporation filed Critical Smithkline Beecham Corporation
Priority to JP2000549282A priority Critical patent/JP2003527067A/ja
Priority to EP99923129A priority patent/EP1085897A4/fr
Publication of WO1999059618A1 publication Critical patent/WO1999059618A1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Definitions

  • ACRP30R1L A HOMOLOG OF ACRP30 (30 KD ADBPOCYTE COMPLEMENT-RELATED PROTEIN)
  • This invention relates to newly identified polypeptides and polynucleotides encoding such polypeptides, to their use in therapy and in identifying compounds which may be agonists, antagonists and/or inhibitors which are potentially useful in therapy, and to production of such polypeptides and polynucleotides.
  • the drug discovery process is currently undergoing a fundamental revolution as it embraces 'functional genomics' , that is, high throughput genome- or gene-based biology. This approach is rapidly superceding earlier approaches based on 'positional cloning' .
  • a phenotype that is a biological function or genetic disease, would be identified and this would then be tracked back to the responsible gene, based on its genetic map position.
  • the present invention relates to ACRP30R1L, in particular ACRP30R1L polypeptides and ACRP30R1L polynucleotides, recombinant materials and methods for their production.
  • the invention relates to methods for using such polypeptides and polynucleotides, including the treatment of cancers, inflammation, cell death, obesity, diabetes, heart disease, cell proliferation, immunity, and energy metabolism and homeostasis, hereinafter referred to as "the Diseases", amongst others.
  • the invention relates to methods for identifying agonists and antagonists/inhibitors using the materials provided by the invention, and treating conditions associated with ACRP30R1L imbalance with the identified compounds.
  • the invention relates to diagnostic assays for detecting diseases associated with inappropriate ACRP30R1L activity or levels. Description of the Invention
  • the present invention relates to ACRP30R1L polypeptides.
  • Such peptides include isolated polypeptides comprising an amino acid sequence which has at least 70% identity, preferably at least 80% identity, more preferably at least 90% identity, yet more preferably at least 95% identity, most preferably at least 97-99% identity, to that of SEQ ID NO:2 over the entire length of SEQ ID NO:2.
  • Such polypeptides include those comprising the amino acid of SEQ ID NO:2.
  • peptides of the present invention include isolated polypeptides in which the amino acid sequence has at least 70% identity, preferably at least 80% identity, more preferably at least 90% identity, yet more preferably at least 95% identity, most preferably at least 97-99% identity, to the amino acid sequence of SEQ ID NO: 2 over the entire length of SEQ ID NO:2.
  • polypeptides include the polypeptide of SEQ ID NO:2.
  • peptides of the present invention include isolated polypeptides encoded by a poly nucleotide comprising the sequence contained in SEQ ID NO: l. Polypeptides of the present invention are believed to be members of the Complement Clq/
  • TNF Tumor Necrosis Factor family of polypeptides. They are therefore of interest because members of this family are known to play a role in role in inflammation, cell proliferation, cell death, immunity, and energy homeostasis processes.
  • ACRP30R1L shows similarity to one member of this family, ACRP30 (Adipocyte Complement-Related Protein of 30 kDa). ACRP30 is expressed exclusively in adipocytes, and its expression is altered in various forms of obesity (Hu,
  • ACRP30 secretion is acutely stimulated by insulin (Scherer, P.E. et al. , J. Biol. Chem. 270, 26746-26749, 1995) and is repressed by chronically elevated levels of insulin.
  • a related molecule, the Hib27 protein from Siberian chipmunks, is also thought to be involved in energy homeostasis, as its expression is specifically extinguished during hibernation (Takamatsu, N. et al., Mol. Cell Biol.13 1516-1521,
  • ACRP30R1L is primarily expressed in heart.
  • ACRP30R1L (SEQ ID NOS: 1 and 2) is a splice variant of the ACRP30R1 gene (disclosed in the parent application having Docket No. GP-70455, filed September 29, 1998), encoding a protein (SEQ ID NO: 2) with a 68 amino acid internal insertion relative to the ACRP30R1 polypeptide. Given that similarity and the similarity of ACRP30R1L to ACRP30, Hib27, Clq complement proteins, TNF, and other members of the TNF superfamily, the encoded protein of
  • ACRP30R1L may play a role in cancers, inflammation, cell death, obesity, diabetes, heart disease, cell proliferation, immunity, and energy metabolism and homeostasis. These properties are hereinafter referred to as "ACRP30R1L activity” or “ACRP30R1L polypeptide activity” or “biological activity of ACRP30R1L” . Also included amongst these activities are antigenic and immunogenic activities of said ACRP30R1L polypeptides, in particular the antigenic and immunogenic activities of the polypeptide of SEQ ID NO:2.
  • a polypeptide of the present invention exhibits at least one biological activity of ACRP30R1L.
  • polypeptides of the present invention may be in the form of the "mature" protein or may be a part of a larger protein such as a fusion protein. It is often advantageous to include an additional amino acid sequence which contains secretory or leader sequences, pro-sequences, sequences which aid in purification such as multiple histidine residues, or an additional sequence for stability during recombinant production.
  • the present invention also includes include variants of the aforementioned polypeptides, that is polypeptides that vary from the referents by conservative amino acid substitutions, whereby a residue is substituted by another with like characteristics. Typical such substitutions are among Ala,
  • Polypeptides of the present invention can be prepared in any suitable manner. Such polypeptides include isolated naturally occurring polypeptides, recombinantly produced polypeptides, synthetically produced polypeptides, or polypeptides produced by a combination of these methods. Means for preparing such polypeptides are well understood in the art.
  • the present invention relates to ACRP30R1L polynucleotides.
  • Such polynucleotides include isolated polynucleotides comprising a nucleotide sequence encoding a polypeptide which has at least 70% identity, preferably at least 80% identity, more preferably at least 90% identity, yet more preferably at least 95% identity, to the amino acid sequence of SEQ ID NO:2, over the entire length of SEQ ID NO:2.
  • polypeptides which have at least 97% identity are highly preferred, whilst those with at least 98-99% identity are more highly preferred, and those with at least 99% identity are most highly preferred.
  • polynucleotides include a polynucleotide comprising the nucleotide sequence contained in SEQ ID NO:l encoding the polypeptide of SEQ ID NO:2.
  • Further polynucleotides of the present invention include isolated polynucleotides comprising a nucleotide sequence that has at least 70% identity, preferably at least 80% identity, more preferably at least 90% identity, yet more preferably at least 95 % identity, to a nucleotide sequence encoding a polypeptide of SEQ ID NO:2, over the entire coding region.
  • polynucleotides which have at least 97% identity are highly preferred, whilst those with at least 98-99% identity are more highly preferred, and those with at least 99% identity are most highly preferred.
  • polynucleotides of the present invention include isolated polynucleotides comprising a nucleotide sequence which has at least 70% identity, preferably at least 80% identity, more preferably at least 90% identity, yet more preferably at least 95 % identity, to SEQ ID NO: l over the entire length of SEQ ID NO: l.
  • polynucleotides which have at least 97% identity are highly preferred, whilst those with at least 98-99% identity are more highly preferred, and those with at least 99% identity are most highly preferred.
  • Such polynucleotides include a polynucleotide comprising the polynucleotide of SEQ ID NO: 1 as well as the polynucleotide of SEQ ID NO: 1.
  • the invention also provides polynucleotides which are complementary to all the above described polynucleotides.
  • the nucleotide sequence of SEQ ID NO: 1 shows homology with a partial human EST sequence, GenBank AA732948, from fetal heart.
  • the nucleotide sequence of SEQ ID NO:l is a cDNA sequence and comprises a polypeptide encoding sequence (nucleotide 15 to 869) encoding a polypeptide of 285 amino acids, the polypeptide of SEQ ID NO:2.
  • the nucleotide sequence encoding the polypeptide of SEQ ID NO: 2 may be identical to the polypeptide encoding sequence contained in SEQ ID NO: 1 or it may be a sequence other than the one contained in SEQ ID NO: 1 , which, as a result of the redundancy (degeneracy) of the genetic code, also encodes the polypeptide of SEQ ID NO:2.
  • the polypeptide of SEQ ID NO:2 is structurally related to other proteins of the Complement Clq/Tumor Necrosis Factor (TNF) family, having homology and/or structural similarity with Bovine Collagen 1(X) Chain (SwissProt sequence CA1A_B0VIN; Thomas, J.T., et al. , 1991, Biochem. J. 273: 141-148) and human ACRP30 (SwissProt sequence
  • Preferred polypeptides and polynucleotides of the present invention are expected to have, inter alia, similar biological functions/properties to their homologous polypeptides and polynucleotides. Furthermore, preferred polypeptides and polynucleotides of the present invention have at least one ACRP30R1L activity.
  • the present invention also relates to partial or other polynucleotide and polypeptide sequences which were first identified prior to the determination of the corresponding full length sequences of SEQ ID NO: 1 and SEQ ID NO:2.
  • the present invention provides for an isolated polynucleotide comprising:
  • nucleotide sequence which has at least 70% identity, preferably at least 80% identity, more preferably at least 90% identity, yet more preferably at least 95% identity, even more preferably at least 97-99% identity to SEQ ID NO: 3 over the entire length of SEQ ID NO: 3;
  • nucleotide sequence which has at least 70% identity, preferably at least 80% identity, more preferably at least 90% identity, yet more preferably at least 95% identity, even more preferably at least 97-99% identity, to SEQ ID NO:3 over the entire length of SEQ ID NO:3;
  • the present invention further provides for a polypeptide which:
  • (a) comprises an amino acid sequence which has at least 70% identity, preferably at least 80% identity, more preferably at least 90% identity, yet more preferably at least 95% identity, most preferably at least 97-99% identity, to that of SEQ ID NO:4 over the entire length of SEQ ID NO:4;
  • (b) has an amino acid sequence which is at least 70% identity, preferably at least 80% identity, more preferably at least 90% identity, yet more preferably at least 95% identity, most preferably at least 97-99% identity, to the amino acid sequence of SEQ ID NO:4 over the entire length of SEQ ID NO:4;
  • (c) comprises the amino acid of SEQ ID NO:4; and (d) is the polypeptide of SEQ ID NO:4; as well as polypeptides encoded by a polynucleotide comprising the sequence contained in SEQ ID NO:3.
  • nucleotide sequence of SEQ ID NO: 3 and the peptide sequence encoded thereby are derived from EST (Expressed Sequence Tag) sequences. It is recognized by those skilled in the art that there will inevitably be some nucleotide sequence reading errors in EST sequences (see
  • nucleotide sequence of SEQ ID NO: 3 and the peptide sequence encoded therefrom are therefore subject to the same inherent limitations in sequence accuracy.
  • the peptide sequence encoded by SEQ ID NO: 3 comprises a region of identity or close homology and/or close structural similarity (for example a conservative amino acid difference) with the closest homologous or structurally similar protein.
  • Polynucleotides of the present invention may be obtained, using standard cloning and screening techniques, from a cDNA library derived from mRNA in cells of human fetal heart, using the expressed sequence tag (EST) analysis (Adams, M.D. , et al. Science (1991) 252: 1651-1656; Adams, M.D. et al. , Nature, (1992) 355:632-634; Adams, M.D. , et al. , Nature (1995) 377 Supp: 3- 174). Polynucleotides of the invention can also be obtained from natural sources such as genomic DNA libraries or can be synthesized using well known and commercially available techniques.
  • EST expressed sequence tag
  • the polynucleotide may include the coding sequence for the mature polypeptide, by itself; or the coding sequence for the mature polypeptide in reading frame with other coding sequences, such as those encoding a leader or secretory sequence, a pre-, or pro- or prepro- protein sequence, or other fusion peptide portions.
  • a marker sequence which facilitates purification of the fused polypeptide can be encoded.
  • the marker sequence is a hexa-histidine peptide, as provided in the pQE vector (Qiagen, Inc.) and described in Gentz et al. , Proc Natl Acad Sci USA (1989) 86:821-824, or is an HA tag.
  • the polynucleotide may also contain non-coding 5' and 3' sequences, such as transcribed, non-translated sequences, splicing and polyadenylation signals, ribosome binding sites and sequences that stabilize mRNA.
  • polypeptide variants which comprise the amino acid sequence of SEQ ID NO:2 and in which several, for instance from 5 to 10, 1 to 5, 1 to 3, 1 to 2 or 1, amino acid residues are substituted, deleted or added, in any combination.
  • Polynucleotides which are identical or sufficiently identical to a nucleotide sequence contained in SEQ ID NO: l may be used as hybridization probes for cDNA and genomic DNA or as primers for a nucleic acid amplification (PCR) reaction, to isolate full-length cDNAs and genomic clones encoding polypeptides of the present invention and to isolate cDNA and genomic clones of other genes (including genes encoding homologs and orthologs from species other than human) that have a high sequence similarity to SEQ ID NO: 1.
  • these nucleotide sequences are 70% identical, preferably 80% identical, more preferably 90% identical, most preferably 95% identical to that of the referent.
  • the probes or primers will generally comprise at least 15 nucleotides, preferably, at least 30 nucleotides and may have at least 50 nucleotides. Particularly preferred probes will have between 30 and 50 nucleotides.
  • a polynucleotide encoding a polypeptide of the present invention may be obtained by a process which comprises the steps of screening an appropriate library under stringent hybridization conditions with a labeled probe having the sequence of SEQ ID NO: 1 or a fragment thereof; and isolating full-length cDNA and genomic clones containing said polynucleotide sequence.
  • Such hybridization techniques are well known to the skilled artisan.
  • Preferred stringent hybridization conditions include overnight incubation at 42°C in a solution comprising: 50% formamide, 5xSSC (150mM NaCl, 15mM trisodium citrate), 50 mM sodium phosphate (pH7.6), 5x Denhardt's solution, 10 % dextran sulfate, and 20 microgram ml denatured, sheared salmon sperm DNA; followed by washing the filters in 0. lx SSC at about 65°C.
  • the present invention also includes polynucleotides obtainable by screening an appropriate library under stringent hybridization conditions with a labeled probe having the sequence of SEQ ID NO: 1 or a fragment thereof.
  • an isolated cDNA sequence will be incomplete, in that the region coding for the polypeptide is cut short at the 5' end of the cDNA. This is a consequence of reverse transcriptase, an enzyme with inherently low 'processivity' (a measure of the ability of the enzyme to remain attached to the template during the polymerization reaction), failing to complete a DNA copy of the mRNA template during 1st strand cDNA synthesis.
  • the PCR reaction is then repeated using 'nested' primers, that is, primers designed to anneal within the amplified product (typically an adaptor specific primer that anneals further 3 ' in the adaptor sequence and a gene specific primer that anneals further 5' in the known gene sequence).
  • primers designed to anneal within the amplified product typically an adaptor specific primer that anneals further 3 ' in the adaptor sequence and a gene specific primer that anneals further 5' in the known gene sequence.
  • the products of this reaction can then be analyzed by DNA sequencing and a full-length cDNA constructed either by joining the product directly to the existing cDNA to give a complete sequence, or carrying out a separate full-length PCR using the new sequence information for the design of the 5' primer.
  • Recombinant polypeptides of the present invention may be prepared by processes well known in the art from genetically engineered host cells comprising expression systems. Accordingly, in a further aspect, the present invention relates to expression systems which comprise a polynucleotide or polynucleotides of the present invention, to host cells which are genetically engineered with such expression systems and to the production of polypeptides of the invention by recombinant techniques.
  • Cell-free translation systems can also be employed to produce such proteins using RNAs derived from the DNA constructs of the present invention.
  • host cells can be genetically engineered to incorporate expression systems or portions thereof for polynucleotides of the present invention.
  • Introduction of polynucleotides into host cells can be effected by methods described in many standard laboratory manuals, such as Davis et al. , Basic Methods in Molecular Biology (1986) and Sambrook et al., Molecular Cloning: A Laboratory Manual, 2nd Ed., Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N. Y. (1989).
  • Preferred such methods include, for instance, calcium phosphate transfection, DEAE-dextran mediated transfection, transvection, microinjection, cationic lipid- mediated transfection, electroporation, transduction, scrape loading, ballistic introduction or infection.
  • bacterial cells such as streptococci, staphylococci, E. coli, Streptomyces and Bacillus subtilis cells
  • fungal cells such as yeast cells and Aspergillus cells
  • insect cells such as Drosophila S2 and Spodoptera Sf9 cells
  • animal cells such as CHO, COS, HeLa, C127, 3T3, BHK, HEK 293 and Bowes melanoma cells
  • plant cells include bacterial cells, such as streptococci, staphylococci, E. coli, Streptomyces and Bacillus subtilis cells
  • fungal cells such as yeast cells and Aspergillus cells
  • insect cells such as Drosophila S2 and Spodoptera Sf9 cells
  • animal cells such as CHO, COS, HeLa, C127, 3T3, BHK, HEK 293 and Bowes melanoma cells
  • expression systems can be used, for instance, chromosomal, episomal and virus-derived systems, e.g., vectors derived from bacterial plasmids, from bacteriophage, from transposons, from yeast episomes, from insertion elements, from yeast chromosomal elements, from viruses such as baculoviruses, papova viruses, such as SV40, vaccinia viruses, adenoviruses, fowl pox viruses, pseudorabies viruses and retroviruses, and vectors derived from combinations thereof, such as those derived from plasmid and bacteriophage genetic elements, such as cosmids and phagemids.
  • the expression systems may contain control regions that regulate as well as engender expression.
  • any system or vector which is able to maintain, propagate or express a polynucleotide to produce a polypeptide in a host may be used.
  • the appropriate nucleotide sequence may be inserted into an expression system by any of a variety of well-known and routine techniques, such as, for example, those set forth in Sambrook et al., MOLECULAR CLONING, A LABORATORY MANUAL (supra).
  • Appropriate secretion signals may be incorporated into the desired polypeptide to allow secretion of the translated protein into the lumen of the endoplasmic reticulum, the periplasmic space or the extracellular environment. These signals may be endogenous to the polypeptide or they may be heterologous signals.
  • a polypeptide of the present invention is to be expressed for use in screening assays, it is generally preferred that the polypeptide be produced at the surface of the cell. In this event, the cells may be harvested prior to use in the screening assay. If the polypeptide is secreted into the medium, the medium can be recovered in order to recover and purify the polypeptide. If produced intracellular ly, the cells must first be lysed before the polypeptide is recovered.
  • Polypeptides of the present invention can be recovered and purified from recombinant cell cultures by well-known methods including ammonium sulfate or ethanol precipitation, acid extraction, anion or cation exchange chromatography, phosphocellulose chromatography, hydrophobic interaction chromatography, affinity chromatography, hydroxylapatite chromatography and lectin chromatography. Most preferably, high performance liquid chromatography is employed for purification. Well known techniques for refolding proteins may be employed to regenerate active conformation when the polypeptide is denatured during isolation and or purification.
  • This invention also relates to the use of polynucleotides of the present invention as diagnostic reagents. Detection of a mutated form of the gene characterized by the polynucleotide of SEQ ID NO: 1
  • NO: 1 which is associated with a dysfunction will provide a diagnostic tool that can add to, or define, a diagnosis of a disease, or susceptibility to a disease, which results from under-expression, over- expression or altered expression of the gene.
  • Individuals carrying mutations in the gene may be detected at the DNA level by a variety of techniques. Nucleic acids for diagnosis may be obtained from a subject's cells, such as from blood, urine, saliva, tissue biopsy or autopsy material. The genomic DNA may be used directly for detection or may be amplified enzymatically by using PCR or other amplification techniques prior to analysis. RNA or cDNA may also be used in similar fashion. Deletions and insertions can be detected by a change in size of the amplified product in comparison to the normal genotype.
  • Point mutations can be identified by hybridizing amplified DNA to labeled ACRP30R1L nucleotide sequences. Perfectly matched sequences can be distinguished from mismatched duplexes by RNase digestion or by differences in melting temperatures. DNA sequence differences may also be detected by alterations in electrophoretic mobility of DNA fragments in gels, with or without denaturing agents, or by direct
  • DNA sequencing (e.g., Myers et al. , Science (1985) 230: 1242). Sequence changes at specific locations may also be revealed by nuclease protection assays, such as RNase and SI protection or the chemical cleavage method (see Cotton et al. , Proc Natl Acad Sci USA (1985) 85: 4397-4401).
  • nuclease protection assays such as RNase and SI protection or the chemical cleavage method (see Cotton et al. , Proc Natl Acad Sci USA (1985) 85: 4397-4401).
  • an array of oligonucleotides probes comprising ACRP30R1L nucleotide sequence or fragments thereof can be constructed to conduct efficient screening of e.g. , genetic mutations.
  • Array technology methods are well known and have general applicability and can be used to address a variety of questions in molecular genetics including gene expression, genetic linkage, and genetic variability (see for example: M.Chee et al., Science, Vol 274, pp 610-613 (1996)).
  • the diagnostic assays offer a process for diagnosing or determining a susceptibility to the Diseases through detection of mutation in the ACRP30R1L gene by the methods described.
  • diseases may be diagnosed by methods comprising determining from a sample derived from a subject an abnormally decreased or increased level of polypeptide or mRNA. Decreased or increased expression can be measured at the RNA level using any of the methods well known in the art for the quantitation of polynucleotides, such as, for example, nucleic acid amplification, for instance PCR, RT-PCR, RNase protection, Northern blotting and other hybridization methods.
  • the present invention relates to a diagonostic kit which comprises:
  • a polynucleotide of the present invention preferably the nucleotide sequence of SEQ ID NO: 1 , or a fragment thereof ;
  • polypeptide of the present invention preferably the polypeptide of SEQ ID NO: 2 or a fragment thereof; or
  • kits an antibody to a polypeptide of the present invention, preferably to the polypeptide of SEQ ID NO:2.
  • kit may comprise a substantial component.
  • Such a kit will be of use in diagnosing a disease or susceptibility to a disease, particularly cancers, inflammation, cell death, obesity, diabetes, heart disease, cell proliferation, immunity, and energy metabolism and homeostasis, amongst others.
  • the nucleotide sequences of the present invention are also valuable for chromosome identification. The sequence is specifically targeted to, and can hybridize with, a particular location on an individual human chromosome.
  • the mapping of relevant sequences to chromosomes is an important first step in correlating those sequences with gene associated disease. Once a sequence has been mapped to a precise chromosomal location, the physical position of the sequence on the chromosome can be correlated with genetic map data. Such data are found in, for example, V. McKusick, Mendelian Inheritance in Man (available on-line through Johns Hopkins University Welch Medical Library). The relationship between genes and diseases that have been mapped to the same chromosomal region are then identified through linkage analysis (coinheritance of physically adjacent genes). The differences in the cDNA or genomic sequence between affected and unaffected individuals can also be determined. If a mutation is observed in some or all of the affected individuals but not in any normal individuals, then the mutation is likely to be the causative agent of the disease. The gene of the present invention maps to human chromosome 5.
  • polypeptides of the invention or their fragments or analogs thereof, or cells expressing them, can also be used as immunogens to produce antibodies immunospecific for polypeptides of the present invention.
  • immunospecific means that the antibodies have substantially greater affinity for the polypeptides of the invention than their affinity for other related polypeptides in the prior art.
  • Antibodies generated against polypeptides of the present invention may be obtained by administering the polypeptides or epitope-bearing fragments, analogs or cells to an animal, preferably a non-human animal, using routine protocols.
  • any technique which provides antibodies produced by continuous cell line cultures can be used. Examples include the hybridoma technique (Kohler, G. and Milstein, C, Nature (1975) 256:495-497), the trioma technique, the human B-cell hybridoma technique (Kozbor et al. , Immunology Today (1983) 4:72) and the EBV-hybridoma technique (Cole et al. , MONOCLONAL ANTIBODIES AND
  • antibodies may be employed to isolate or to identify clones expressing the polypeptide or to purify the polypeptides by affinity chromatography.
  • Antibodies against polypeptides of the present invention may also be employed to treat the
  • the present invention relates to genetically engineered soluble fusion proteins comprising a polypeptide of the present invention, or a fragment thereof, and various portions of the constant regions of heavy or light chains of immunoglobulins of various subclasses (IgG, IgM, IgA, IgE).
  • immunoglobulin is the constant part of the heavy chain of human IgG, particularly IgGl , where fusion takes place at the hinge region.
  • the Fc part can be removed simply by incorporation of a cleavage sequence which can be cleaved with blood clotting factor Xa.
  • this invention relates to processes for the preparation of these fusion proteins by genetic engineering, and to the use thereof for drug screening, diagnosis and therapy.
  • a further aspect of the invention also relates to polynucleotides encoding such fusion proteins. Examples of fusion protein technology can be found in International Patent Application Nos. W094/29458 and W094/22914.
  • Another aspect of the invention relates to a method for inducing an immunological response in a mammal which comprises inoculating the mammal with a polypeptide of the present invention, adequate to produce antibody and/or T cell immune response to protect said animal from the Diseases hereinbefore mentioned, amongst others.
  • Yet another aspect of the invention relates to a method of inducing immunological response in a mammal which comprises, delivering a polypeptide of the present invention via a vector directing expression of the polynucleotide and coding for the polypeptide in vivo in order to induce such an immunological response to produce antibody to protect said animal from diseases.
  • a further aspect of the invention relates to an immunological/vaccine formulation (composition) which, when introduced into a mammalian host, induces an immunological response in that mammal to a polypeptide of the present invention wherein the composition comprises a polypeptide or polynucleotide of the present invention.
  • the vaccine formulation may further comprise a suitable carrier. Since a polypeptide may be broken down in the stomach, it is preferably administered parenterally (for instance, subcutaneous, intramuscular, intravenous, or intradermal injection).
  • Formulations suitable for parenteral administration include aqueous and non-aqueous sterile injection solutions which may contain anti-oxidants, buffers, bacteriostats and solutes which render the formulation isotonic with the blood of the recipient; and aqueous and non-aqueous sterile suspensions which may include suspending agents or thickening agents.
  • the formulations may be presented in unit-dose or multi-dose containers, for example, sealed ampoules and vials and may be stored in a freeze-dried condition requiring only the addition of the sterile liquid carrier immediately prior to use.
  • the vaccine formulation may also include adjuvant systems for enhancing the immunogenicity of the formulation, such as oil-in water systems and other systems known in the art. The dosage will depend on the specific activity of the vaccine and can be readily determined by routine experimentation.
  • Polypeptides of the present invention are responsible for many biological functions, including many disease states, in particular the Diseases hereinbefore mentioned. It is therefore desirous to devise screening methods to identify compounds which stimulate or which inhibit the function of the polypeptide. Accordingly, in a further aspect, the present invention provides for a method of screening compounds to identify those which stimulate or which inhibit the function of the polypeptide.
  • agonists or antagonists may be employed for therapeutic and prophylactic purposes for such Diseases as hereinbefore mentioned.
  • Compounds may be identified from a variety of sources, for example, cells, cell-free preparations, chemical libraries, and natural product mixtures. Such agonists, antagonists or inhibitors so-identified may be natural or modified substrates, ligands, receptors, enzymes, etc. , as the case may be, of the polypeptide; or may be structural or functional mimetics thereof (see Coligan et al. , Current Protocols in Immunology 1(2): Chapter 5 (1991)).
  • the screening method may simply measure the binding of a candidate compound to the polypeptide, or to cells or membranes bearing the polypeptide, or a fusion protein thereof by means of a label directly or indirectly associated with the candidate compound.
  • the screening method may involve competition with a labeled competitor.
  • these screening methods may test whether the candidate compound results in a signal generated by activation or inhibition of the polypeptide, using detection systems appropriate to the cells bearing the polypeptide. Inhibitors of activation are generally assayed in the presence of a known agonist and the effect on activation by the agonist by the presence of the candidate compound is observed.
  • Constitutively active polypeptides may be employed in screening methods for inverse agonists or inhibitors, in the absence of an agonist or inhibitor, by testing whether the candidate compound results in inhibition of activation of the polypeptide. Further, the screening methods may simply comprise the steps of mixing a candidate compound with a solution containing a polypeptide of the present invention, to form a mixture, measuring ACRP30R1L activity in the mixture, and comparing the ACRP30R1L activity of the mixture to a standard. Fusion proteins, such as those made from Fc portion and ACRP30R1L polypeptide, as hereinbefore described, can also be used for high-throughput screening assays to identify antagonists for the polypeptide of the present invention (see D. Bennett et al. , J Mol Recognition, 8:52-58 (1995); and K. Johanson et al. , J Biol Chem, 270(16):9459-9471 (1995)).
  • polypeptides and antibodies to the polypeptide of the present invention may also be used to configure screening methods for detecting the effect of added compounds on the production of mRNA and polypeptide in cells.
  • an ELISA assay may be constructed for measuring secreted or cell associated levels of polypeptide using monoclonal and polyclonal antibodies by standard methods known in the art. This can be used to discover agents which may inhibit or enhance the production of polypeptide (also called antagonist or agonist, respectively) from suitably manipulated cells or tissues.
  • the polypeptide may be used to identify membrane bound or soluble receptors, if any, through standard receptor binding techniques known in the art. These include, but are not limited to, ligand binding and crosslinking assays in which the polypeptide is labeled with a radioactive isotope (for instance, ⁇ ), chemically modified (for instance, biotinylated), or fused to a peptide sequence suitable for detection or purification, and incubated with a source of the putative receptor (cells, cell membranes, cell supernatants, tissue extracts, bodily fluids). Other methods include biophysical techniques such as surface plasmon resonance and spectroscopy. These screening methods may also be used to identify agonists and antagonists of the polypeptide which compete with the binding of the polypeptide to its receptors, if any. Standard methods for conducting such assays are well understood in the art.
  • polypeptide antagonists include antibodies or, in some cases, oligonucleotides or proteins which are closely related to the ligands, substrates, receptors, enzymes, etc. , as the case may be, of the polypeptide, e.g. , a fragment of the ligands, substrates, receptors, enzymes, etc.; or small molecules which bind to the polypeptide of the present invention but do not elicit a response, so that the activity of the polypeptide is prevented.
  • the present invention relates to a screening kit for identifying agonists, antagonists, ligands, receptors, substrates, enzymes, etc. for polypeptides of the present invention; or compounds which decrease or enhance the production of such polypeptides, which comprises:
  • a polypeptide of the present invention may also be used in a method for the structure-based design of an agonist, antagonist or inhibitor of the polypeptide, by: (a) determining in the first instance the three-dimensional structure of the polypeptide;
  • the present invention provides methods of treating abnormal conditions such as, for instance, cancers, inflammation, cell death, obesity, diabetes, heart disease, cell proliferation, immunity, and energy metabolism and homeostasis, related to either an excess of, or an under-expression of, ACRP30R1L polypeptide activity.
  • abnormal conditions such as, for instance, cancers, inflammation, cell death, obesity, diabetes, heart disease, cell proliferation, immunity, and energy metabolism and homeostasis, related to either an excess of, or an under-expression of, ACRP30R1L polypeptide activity.
  • One approach comprises administering to a subject in need thereof an inhibitor compound (antagonist) as hereinabove described, optionally in combination with a pharmaceutically acceptable carrier, in an amount effective to inhibit the function of the polypeptide, such as, for example, by blocking the binding of ligands, substrates, receptors, enzymes, etc., or by inhibiting a second signal, and thereby alleviating the abnormal condition.
  • an inhibitor compound as hereinabove described
  • a pharmaceutically acceptable carrier in an amount effective to inhibit the function of the polypeptide, such as, for example, by blocking the binding of ligands, substrates, receptors, enzymes, etc., or by inhibiting a second signal, and thereby alleviating the abnormal condition.
  • soluble forms of the polypeptides still capable of binding the ligand, substrate, enzymes, receptors, etc. in competition with endogenous polypeptide may be administered. Typical examples of such competitors include fragments of the ACRP30R1L polypeptide.
  • expression of the gene encoding endogenous ACRP30R1L polypeptide can be inhibited using expression blocking techniques.
  • Known such techniques involve the use of antisense sequences, either internally generated or separately administered (see, for example, O'Connor, J Neurochem (1991) 56:560 in Oligodeoxynucleotides as Antisense Inhibitors of Gene Expression, CRC Press, Boca Raton, FL (1988)).
  • oligonucleotides which form triple helices with the gene can be supplied (see, for example, Lee et al., Nucleic Acids Res (1979) 3:173; Cooney et al., Science (1988) 241:456; Dervan et al., Science (1991) 251 : 1360). These oligomers can be administered per se or the relevant oligomers can be expressed in vivo. For treating abnormal conditions related to an under-expression of ACRP30R1L and its activity, several approaches are also available.
  • One approach comprises administering to a subject a therapeutically effective amount of a compound which activates a polypeptide of the present invention, i.e., an agonist as described above, in combination with a pharmaceutically acceptable carrier, to thereby alleviate the abnormal condition.
  • gene therapy may be employed to effect the endogenous production of ACRP30R1L by the relevant cells in the subject.
  • a polynucleotide of the invention may be engineered for expression in a replication defective retroviral vector, as discussed above.
  • the retroviral expression construct may then be isolated and introduced into a packaging cell transduced with a retroviral plasmid vector containing RNA encoding a polypeptide of the present invention such that the packaging cell now produces infectious viral particles containing the gene of interest.
  • These producer cells may be administered to a subject for engineering cells in vivo and expression of the polypeptide in vivo.
  • Another approach is to administer a therapeutic amount of a polypeptide of the present invention in combination with a suitable pharmaceutical carrier.
  • the present invention provides for pharmaceutical compositions comprising a therapeutically effective amount of a polypeptide, such as the soluble form of a polypeptide of the present invention, agonist/antagonist peptide or small molecule compound, in combination with a pharmaceutically acceptable carrier or excipient.
  • a pharmaceutically acceptable carrier or excipient include, but are not limited to, saline, buffered saline, dextrose, water, glycerol, ethanol, and combinations thereof.
  • the invention further relates to pharmaceutical packs and kits comprising one or more containers filled with one or more of the ingredients of the aforementioned compositions of the invention.
  • Polypeptides and other compounds of the present invention may be employed alone or in conjunction with other compounds, such as therapeutic compounds.
  • composition will be adapted to the route of administration, for instance by a systemic or an oral route.
  • Preferred forms of systemic administration include injection, typically by intravenous injection. Other injection routes, such as subcutaneous, intramuscular, or intraperitoneal, can be used.
  • Alternative means for systemic administration include transmucosal and transdermal administration using penetrants such as bile salts or fusidic acids or other detergents.
  • penetrants such as bile salts or fusidic acids or other detergents.
  • oral administration may also be possible. Administration of these compounds may also be topical and/or localized, in the form of salves, pastes, gels, and the like.
  • the dosage range required depends on the choice of peptide or other compounds of the present invention, the route of administration, the nature of the formulation, the nature of the subject's condition, and the judgment of the attending practitioner. Suitable dosages, however, are in the range of 0.1-100 ⁇ g/kg of subject. Wide variations in the needed dosage, however, are to be expected in view of the variety of compounds available and the differing efficiencies of various routes of administration. For example, oral administration would be expected to require higher dosages than administration by intravenous injection. Variations in these dosage levels can be adjusted using standard empirical routines for optimization, as is well understood in the art.
  • Polypeptides used in treatment can also be generated endogenously in the subject, in treatment modalities often referred to as "gene therapy" as described above.
  • cells from a subject may be engineered with a polynucleotide, such as a DNA or RNA, to encode a polypeptide ex vivo, and for example, by the use of a retroviral plasmid vector. The cells are then introduced into the subject.
  • a polynucleotide such as a DNA or RNA
  • Polynucleotide and polypeptide sequences form a valuable information resource with which to identify further sequences of similar homology. This is most easily facilitated by storing the sequence in a computer readable medium and then using the stored data to search a sequence database using well known searching tools, such as GCC. Accordingly, in a further aspect, the present invention provides for a computer readable medium having stored thereon a polynucleotide comprising the sequence of SEQ ID NO: l and/ or a polypeptide sequence encoded thereby.
  • the following definitions are provided to facilitate understanding of certain terms used frequently hereinbefore.
  • Antibodies as used herein includes polyclonal and monoclonal antibodies, chimeric, single chain, and humanized antibodies, as well as Fab fragments, including the products of an Fab or other immunoglobulin expression library.
  • Isolated means altered “by the hand of man” from the natural state. If an "isolated” composition or substance occurs in nature, it has been changed or removed from its original environment, or both.
  • a polynucleotide or a polypeptide naturally present in a living animal is not “isolated,” but the same polynucleotide or polypeptide separated from the coexisting materials of its natural state is “isolated”, as the term is employed herein.
  • Polynucleotide generally refers to any polyribonucleotide or polydeoxribonucleotide, which may be unmodified RNA or DNA or modified RNA or DNA.
  • Polynucleotides include, without limitation, single- and double-stranded DNA, DNA that is a mixture of single- and double-stranded regions, single- and double-stranded RNA, and RNA that is mixture of single- and double-stranded regions, hybrid molecules comprising DNA and RNA that may be single- stranded or, more typically, double-stranded or a mixture of single- and double-stranded regions.
  • polynucleotide refers to triple-stranded regions comprising RNA or DNA or both
  • polynucleotide also includes DNAs or RNAs containing one or more modified bases and DNAs or RNAs with backbones modified for stability or for other reasons.
  • Modified bases include, for example, tritylated bases and unusual bases such as inosine.
  • polynucleotide embraces chemically, enzymatically or metabolically modified forms of polynucleotides as typically found in nature, as well as the chemical forms of DNA and RNA characteristic of viruses and cells.
  • Polynucleotide also embraces relatively short polynucleotides, often referred to as oligonucleotides.
  • Polypeptide refers to any peptide or protein comprising two or more amino acids joined to each other by peptide bonds or modified peptide bonds, i.e., peptide isosteres.
  • Polypeptide refers to both short chains, commonly referred to as peptides, oligopeptides or oligomers, and to longer chains, generally referred to as proteins. Polypeptides may contain amino acids other than the 20 gene-encoded amino acids.
  • Polypeptides include amino acid sequences modified either by natural processes, such as post-translational processing, or by chemical modification techniques which are well known in the art. Such modifications are well described in basic texts and in more detailed monographs, as well as in a voluminous research literature.
  • Modifications may occur anywhere in a polypeptide, including the peptide backbone, the amino acid side-chains and the amino or carboxyl termini. It will be appreciated that the same type of modification may be present to the same or varying degrees at several sites in a given polypeptide. Also, a given polypeptide may contain many types of modifications. Polypeptides may be branched as a result of ubiquitination, and they may be cyclic, with or without branching. Cyclic, branched and branched cyclic polypeptides may result from post-translation natural processes or may be made by synthetic methods.
  • Modifications include acetylation, acylation, ADP-ribosylation, amidation, covalent attachment of flavin, covalent attachment of a heme moiety, covalent attachment of a nucleotide or nucleotide derivative, covalent attachment of a lipid or lipid derivative, covalent attachment of phosphotidylinositol, cross-linking, cyclization, disulfide bond formation, demethylation, formation of covalent cross-links, formation of cystine, formation of pyroglutamate, formylation, gamma-carboxylation, glycosylation, GPI anchor formation, hydroxylation, iodination, methylation, myristoylation, oxidation, proteolytic processing, phosphorylation, prenylation, racemization, selenoylation, sulfation, transfer-RNA mediated addition of amino acids to proteins such as arginylation, and ubiquitination (see, for instance, PROTEINS - STR
  • Variant refers to a polynucleotide or polypeptide that differs from a reference polynucleotide or polypeptide, but retains essential properties.
  • a typical variant of a polynucleotide differs in nucleotide sequence from another, reference polynucleotide. Changes in the nucleotide sequence of the variant may or may not alter the amino acid sequence of a polypeptide encoded by the reference polynucleotide. Nucleotide changes may result in amino acid substitutions, additions, deletions, fusions and truncations in the polypeptide encoded by the reference sequence, as discussed below.
  • a typical variant of a polypeptide differs in amino acid sequence from another, reference polypeptide.
  • a variant and reference polypeptide may differ in amino acid sequence by one or more substitutions, additions, deletions in any combination.
  • a substituted or inserted amino acid residue may or may not be one encoded by the genetic code.
  • a variant of a polynucleotide or polypeptide may be a naturally occurring such as an allelic variant, or it may be a variant that is not known to occur naturally. Non-naturally occurring variants of polynucleotides and polypeptides may be made by mutagenesis techniques or by direct synthesis.
  • Identity is a relationship between two or more polypeptide sequences or two or more polynucleotide sequences, as determined by comparing the sequences.
  • identity also means the degree of sequence relatedness between polypeptide or polynucleotide sequences, as the case may be, as determined by the match between strings of such sequences.
  • Identity and similarity can be readily calculated by known methods, including but not limited to those described in (Computational Molecular Biology, Lesk, A.M. , ed., Oxford University Press, New York, 1988; Biocomputing: Informatics and Genome Projects, Smith, D.W., ed., Academic Press, New York, 1993; Computer Analysis of Sequence Data, Part I,
  • Preferred computer program methods to determine identity and similarity between two sequences include, but are not limited to, the GCG program package (Devereux, J. , et al. , Nucleic Acids Research 12(1): 387 (1984)), BLASTP, BLASTN, and FASTA (Atschul, S.F. et al. , J. Molec. Biol. 215: 403-410 (1990).
  • the BLAST X program is publicly available from NCBI and other sources (BLAST
  • Preferred parameters for polypeptide sequence comparison include the following: 1) Algorithm: Needleman and Wunsch, J. Mol Biol. 48: 443-453 (1970)
  • Gap Length Penalty 4 A program useful with these parameters is publicly available as the "gap" program from
  • Preferred parameters for polynucleotide comparison include the following:
  • Gap Penalty 50 Gap Length Penalty: 3
  • a polynucleotide sequence of the present invention may be identical to the reference sequence of SEQ ID NO: 1, that is be 100% identical, or it may include up to a certain integer number of nucleotide alterations as compared to the reference sequence.
  • Such alterations are selected from the group consisting of at least one nucleotide deletion, substitution, including transition and transversion, or insertion, and wherein said alterations may occur at the 5' or 3' terminal positions of the reference nucleotide sequence or anywhere between those terminal positions, interspersed either individually among the nucleotides in the reference sequence or in one or more contiguous groups within the reference sequence.
  • the number of nucleotide alterations is determined by multiplying the total number of nucleotides in SEQ ID NO: 1 by the numerical percent of the respective percent identity (divided by 100) and subtracting that product from said total number of nucleotides in SEQ ID NO: l, or:
  • n n is the number of nucleotide alterations
  • x n is the total number of nucleotides in SEQ
  • any non- integer product of x n and y is rounded down to the nearest integer prior to subtracting it from x n .
  • Alterations of a polynucleotide sequence encoding the polypeptide of SEQ ID NO:2 may create nonsense, missense or frameshift mutations in this coding sequence and thereby alter the polypeptide encoded by the polynucleotide following such alterations.
  • a polypeptide sequence of the present invention may be identical to the reference sequence of SEQ ID NO:2, that is be 100% identical, or it may include up to a certain integer number of amino acid alterations as compared to the reference sequence such that the % identity is less than 100%.
  • Such alterations are selected from the group consisting of at least one amino acid deletion, substitution, including conservative and non-conservative substitution, or insertion, and wherein said alterations may occur at the amino- or carboxy-terminal positions of the reference polypeptide sequence or anywhere between those terminal positions, interspersed either individually among the amino acids in the reference sequence or in one or more contiguous groups within the reference sequence.
  • the number of amino acid alterations for a given % identity is determined by multiplying the total number of amino acids in SEQ ID NO: 2 by the numerical percent of the respective percent identity(divided by 100) and then subtracting that product from said total number of amino acids in SEQ ID NO:2, or:
  • n a is the number of amino acid alterations
  • x a is the total number of amino acids in SEQ ID NO:2
  • y is, for instance 0.70 for 70%, 0.80 for 80%, 0.85 for 85% etc. , and wherein any non-integer product of x a and y is rounded down to the nearest integer prior to subtracting it from x a .
  • Fusion protein refers to a protein encoded by two, often unrelated, fused genes or fragments thereof.
  • EP-A-0464 discloses fusion proteins comprising various portions of constant region of immunoglobulin molecules together with another human protein or part thereof.
  • employing an immunoglobulin Fc region as a part of a fusion protein is advantageous for use in therapy and diagnosis resulting in, for example, improved pharmacokinetic properties [see, e.g., EP-A 0232 262].
  • ACRP30R1L The expression pattern of ACRP30R1L mRNAs in 8 human tissues (heart, brain, placenta, lung, liver, muscle, kidney and pancreas) was examined by Northern analysis.
  • a probe to ACRP30R1L hybridizes to two mRNAs: one is ⁇ 1.2 kb in size, the other is ⁇ 2.4 kb.
  • the 1.2 kb mRNA is most abundant in heart; while the 2.4kb mRNA is most abundant in placenta. Lower levels of expression of both transcripts are also observed in muscle.
  • SEQUENCE LISTING FREE TEXT SEQUENCE INFORMATION SEQ ID NO:l

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Toxicology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

L'invention concerne les polypeptides et les polynucléotides ACRP30R1L. L'invention concerne également des procédés permettant de produire ces polypeptides au moyen de techniques de recombinaison. L'invention concerne, en outre, des procédés permettant d'utiliser les polypeptides et les polynucléotides ACRP30R1L dans une thérapie. L'invention concerne également des dosages diagnostiques pour ces polypeptides et polynucléotides ACRP30R1L.
PCT/US1999/010822 1998-05-21 1999-05-18 Acrp30r1l, homologue de acrp30 (proteine associee a un complement de l'adipocyte 30 kd) WO1999059618A1 (fr)

Priority Applications (2)

Application Number Priority Date Filing Date Title
JP2000549282A JP2003527067A (ja) 1998-05-21 1999-05-18 Ａｃｒｐ３０（３０ｋｄの脂肪細胞補体関連タンパク質）の相同体ａｃｒｐ３０ｒ１ｌ
EP99923129A EP1085897A4 (fr) 1998-05-21 1999-05-18 Acrp30r1l, homologue de acrp30 (proteine associee a un complement de l'adipocyte 30 kd)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US8656298P 1998-05-21 1998-05-21
US60/086,562 1998-05-21
US16235298A 1998-09-29 1998-09-29
US09/162,352 1998-09-29
US17550198A 1998-10-20 1998-10-20
US09/175,501 1998-10-20

Publications (1)

Publication Number Publication Date
WO1999059618A1 true WO1999059618A1 (fr) 1999-11-25

Family

ID=27375431

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1999/010822 WO1999059618A1 (fr) 1998-05-21 1999-05-18 Acrp30r1l, homologue de acrp30 (proteine associee a un complement de l'adipocyte 30 kd)

Country Status (3)

Country Link
EP (1) EP1085897A4 (fr)
JP (1) JP2003527067A (fr)
WO (1) WO1999059618A1 (fr)

Cited By (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000063376A1 (fr) * 1999-04-20 2000-10-26 Zymogenetics, Inc. Zacrp2 homologues proteiques apparentes au complement adipocytaire
EP1173483A4 (fr) * 1999-04-28 2002-07-10 Smithkline Beecham Corp Acrp30r1m, homologue d'acrp30
US6448221B1 (en) 1999-02-19 2002-09-10 Zymogenetics, Inc. Methods of promoting blood flow within the vasculature of a mammal
WO2003009865A1 (fr) * 2001-07-25 2003-02-06 Genset S.A. Agonistes et antagonistes d'energene utilises dans le traitement de troubles metaboliques
WO2003009861A1 (fr) * 2001-07-24 2003-02-06 Genset S.A. Agonistes et antagonistes de metabolix utilises dans le traitement des troubles metaboliques
WO2003009863A1 (fr) * 2001-07-26 2003-02-06 Genset S.A. Agonistes et antagonistes de la cofoxine utilises pour traiter des troubles metaboliques
WO2003009864A1 (fr) * 2001-07-23 2003-02-06 Genset S.A. Agonistes et antagonistes de disomet pour le traitement de troubles metaboliques
WO2003009862A1 (fr) * 2001-07-20 2003-02-06 Genset S.A. Agonistes et antagonistes vis-a-vis du modumet utilises dans le traitement des troubles metaboliques
WO2003011319A1 (fr) * 2001-08-02 2003-02-13 Genset S.A Agonistes et antagonistes de xobesine utilises dans le traitement des troubles metaboliques
WO2003011323A1 (fr) * 2001-07-30 2003-02-13 Genset S.A. Agonistes et antagonistes du contabix, destines au traitement de troubles metaboliques
WO2003011318A1 (fr) * 2001-08-01 2003-02-13 Genset S.A. Agonistes et antagonistes de famoset utilisables pour le traitement de troubles metaboliques
WO2003011324A1 (fr) * 2001-07-31 2003-02-13 Genset S.A. Agonistes et d'antagonistes du moxifin pour le traitement de troubles metaboliques
WO2003011325A1 (fr) * 2001-07-27 2003-02-13 Genset S.A. Agonistes et d'antagonistes de moceptine pour le traitement de troubles metaboliques
WO2003011320A1 (fr) * 2001-08-02 2003-02-13 Genset S.A. Agonistes et antagonistes d'obesingen dans le traitement des troubles metaboliques
WO2003011321A1 (fr) * 2001-07-31 2003-02-13 Genset S.A. Agonistes et antagonistes de la cobesine pour le traitement des troubles metaboliques
WO2003011322A1 (fr) * 2001-08-02 2003-02-13 Genset S.A. Agonistes et antagonistes de la genoxine destines a etre utilises dans le traitement des troubles metaboliques
WO2003013584A1 (fr) * 2001-08-09 2003-02-20 Genset S.A. Agonistes et antagonistes xafinix destines a etre utilises dans le traitement des troubles metaboliques
WO2003013580A1 (fr) * 2001-08-03 2003-02-20 Genset S.A. Traitement des troubles du metabolisme a l'aide d'agonistes et d'antagonistes xidatine
WO2003013581A1 (fr) * 2001-08-03 2003-02-20 Genset S.A. Agonistes et antagonistes de la genceptine pour le traitement des troubles metaboliques
WO2003013585A1 (fr) * 2001-08-08 2003-02-20 Genset S.A. Agonistes et antagonistes de la mifaxine convenant au traitement de troubles du metabolisme au moyen
WO2003013583A1 (fr) * 2001-08-10 2003-02-20 Genset S.A. Agonistes et antagonistes de faxigene dans le traitement de troubles metaboliques
WO2003013582A1 (fr) * 2001-08-06 2003-02-20 Genset S.A. Agonistes et antagonistes de genoxit destines au traitement des troubles du metabolisme
WO2003013579A1 (fr) * 2001-08-03 2003-02-20 Genset S.A. Agonistes et antagonistes de lipergix destines au traitement des troubles metaboliques
WO2003013578A1 (fr) * 2001-08-07 2003-02-20 Genset S.A. Traitement des troubles metabolique au moyen d'agonistes et d'antagonistes d'omoxine
WO2002046417A3 (fr) * 2000-12-07 2003-03-20 Zymogenetics Inc Proteine associee au complement adipocyte zacrp3x2
WO2003022299A1 (fr) * 2001-08-01 2003-03-20 Genset S.A. Agonistes et antagonistes de genobix utiles dans le traitement des troubles metaboliques
WO2003026695A1 (fr) * 2001-09-21 2003-04-03 Genset S.A. Agonistes et antagonistes de cylixine permettant de traiter des troubles du metabolisme
US6544946B1 (en) 1999-02-19 2003-04-08 Zymogenetics, Inc. Inhibitors for use in hemostasis and immune function
WO2003041730A1 (fr) * 2001-11-16 2003-05-22 Genset S.A. Agonistes et antagonistes de ditacine utilises pour traiter des troubles du metabolisme
WO2003045421A1 (fr) * 2001-11-28 2003-06-05 Genset S.A. Agonistes et antagonistes de ryzn pour le traitement de troubles metaboliques
WO2002070704A3 (fr) * 2000-11-29 2003-06-05 Zymogenetics Inc Proteine zacrp11 apparentee a un complement d'adipocyte
WO2003045422A1 (fr) * 2001-11-29 2003-06-05 Genset S.A. Agonistes et antagonistes de la prolixine pour le traitement des troubles metaboliques
WO2003047615A1 (fr) * 2001-12-05 2003-06-12 Genset S.A. Traitement de troubles metaboliques au moyen d'agonistes et d'antagonistes de dexar
WO2003047614A1 (fr) * 2001-12-05 2003-06-12 Genset S.A. Agoniste et antagonistes de redax pour traiter les troubles du metabolisme
WO2003049757A1 (fr) * 2001-12-12 2003-06-19 Genset S.A. Agonistes et antagonistes de glucomin pour le traitement de troubles du metabolisme
WO2003049756A1 (fr) * 2001-12-13 2003-06-19 Genset S.A. Agonistes et antagonistes de glucomine a utiliser dans le traitement de troubles metaboliques
WO2003049759A1 (fr) * 2001-12-13 2003-06-19 Genset S.A. Agonistes et antagonistes d'oxifan pour le traitement de troubles du metabolisme
WO2003049758A1 (fr) * 2001-12-13 2003-06-19 Genset S.A. Agonistes et antagonistes d'energene pour le traitement de troubles du metabolisme
WO2003051386A1 (fr) * 2001-12-14 2003-06-26 Genset S.A. Agonistes et antagonistes de glucoset a utiliser dans le traitement de troubles metaboliques
WO2003055509A1 (fr) * 2001-12-26 2003-07-10 Genset S.A. Agonistes et antagonistes du bromix servant au traitement de troubles metaboliques
US6620909B1 (en) 1999-04-20 2003-09-16 Zymogenetics, Inc. Adipocyte complement related protein homolog zacrp2
WO2003077939A1 (fr) * 2002-03-19 2003-09-25 Genset Sa Traitement de troubles du metabolisme par des agonistes et antagonistes d'un membre (fradj and/or cryptic) de la famille des recepteurs du tnf
WO2003013604A3 (fr) * 2001-08-09 2003-10-09 Genset Sa Traitement des troubles metaboliques par les agonistes et les antagonistes de migenix
US7034132B2 (en) 2001-06-04 2006-04-25 Anderson David W Therapeutic polypeptides, nucleic acids encoding same, and methods of use
US7863243B2 (en) 2003-11-04 2011-01-04 Sankyo Company, Limited Anti-tumor agent

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
CHEMICAL ABSTRACTS, vol. 119, no. 17, 25 October 1993, Columbus, Ohio, US; abstract no. 175149H, ADAMS ET AL: "Rapid cDNA sequencing (expressed sequence tags) from a directionally cloned human infant brain cDNA library" XP002921075 *
FREIFELDER D: "RADII OF GYRATION OF SELECTED MOLECULES", PHYSICAL BIOCHEMISTRY, XX, XX, 1 January 1982 (1982-01-01), XX, pages 17 - 34, XP002921076 *
NAT. GENET., vol. 4(4), 1993, pages 373 - 380 *
See also references of EP1085897A4 *

Cited By (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6448221B1 (en) 1999-02-19 2002-09-10 Zymogenetics, Inc. Methods of promoting blood flow within the vasculature of a mammal
US6544946B1 (en) 1999-02-19 2003-04-08 Zymogenetics, Inc. Inhibitors for use in hemostasis and immune function
US7208578B2 (en) 1999-04-20 2007-04-24 Zymogenetics, Inc. Adipocyte complement related protein homolog zacrp2
WO2000063376A1 (fr) * 1999-04-20 2000-10-26 Zymogenetics, Inc. Zacrp2 homologues proteiques apparentes au complement adipocytaire
US6620909B1 (en) 1999-04-20 2003-09-16 Zymogenetics, Inc. Adipocyte complement related protein homolog zacrp2
US6921649B2 (en) 1999-04-20 2005-07-26 Zymogenetics, Inc. Polynucleotide encoding adipocyte complement related protein homolog zacrp2
EP1173483A4 (fr) * 1999-04-28 2002-07-10 Smithkline Beecham Corp Acrp30r1m, homologue d'acrp30
WO2002070704A3 (fr) * 2000-11-29 2003-06-05 Zymogenetics Inc Proteine zacrp11 apparentee a un complement d'adipocyte
US7169897B2 (en) 2000-12-07 2007-01-30 Zymogenetics, Inc. Adipocyte complement related protein ZACRP3X2
WO2002046417A3 (fr) * 2000-12-07 2003-03-20 Zymogenetics Inc Proteine associee au complement adipocyte zacrp3x2
US6692748B2 (en) 2000-12-07 2004-02-17 Zymogenetics, Inc. Adipocyte complement related protein zacrp3x2 and nucleic acids encoding zacrp3x2
US7034132B2 (en) 2001-06-04 2006-04-25 Anderson David W Therapeutic polypeptides, nucleic acids encoding same, and methods of use
WO2003009862A1 (fr) * 2001-07-20 2003-02-06 Genset S.A. Agonistes et antagonistes vis-a-vis du modumet utilises dans le traitement des troubles metaboliques
WO2003009864A1 (fr) * 2001-07-23 2003-02-06 Genset S.A. Agonistes et antagonistes de disomet pour le traitement de troubles metaboliques
WO2003009861A1 (fr) * 2001-07-24 2003-02-06 Genset S.A. Agonistes et antagonistes de metabolix utilises dans le traitement des troubles metaboliques
WO2003009865A1 (fr) * 2001-07-25 2003-02-06 Genset S.A. Agonistes et antagonistes d'energene utilises dans le traitement de troubles metaboliques
WO2003009863A1 (fr) * 2001-07-26 2003-02-06 Genset S.A. Agonistes et antagonistes de la cofoxine utilises pour traiter des troubles metaboliques
WO2003011325A1 (fr) * 2001-07-27 2003-02-13 Genset S.A. Agonistes et d'antagonistes de moceptine pour le traitement de troubles metaboliques
WO2003011323A1 (fr) * 2001-07-30 2003-02-13 Genset S.A. Agonistes et antagonistes du contabix, destines au traitement de troubles metaboliques
WO2003011324A1 (fr) * 2001-07-31 2003-02-13 Genset S.A. Agonistes et d'antagonistes du moxifin pour le traitement de troubles metaboliques
WO2003011321A1 (fr) * 2001-07-31 2003-02-13 Genset S.A. Agonistes et antagonistes de la cobesine pour le traitement des troubles metaboliques
WO2003022299A1 (fr) * 2001-08-01 2003-03-20 Genset S.A. Agonistes et antagonistes de genobix utiles dans le traitement des troubles metaboliques
WO2003011318A1 (fr) * 2001-08-01 2003-02-13 Genset S.A. Agonistes et antagonistes de famoset utilisables pour le traitement de troubles metaboliques
US7276342B2 (en) 2001-08-02 2007-10-02 Serono Genetics Institute S.A. Xobesin agonists and antagonists for the treatment of metabolic disorders
WO2003011322A1 (fr) * 2001-08-02 2003-02-13 Genset S.A. Agonistes et antagonistes de la genoxine destines a etre utilises dans le traitement des troubles metaboliques
WO2003011320A1 (fr) * 2001-08-02 2003-02-13 Genset S.A. Agonistes et antagonistes d'obesingen dans le traitement des troubles metaboliques
WO2003011319A1 (fr) * 2001-08-02 2003-02-13 Genset S.A Agonistes et antagonistes de xobesine utilises dans le traitement des troubles metaboliques
WO2003013581A1 (fr) * 2001-08-03 2003-02-20 Genset S.A. Agonistes et antagonistes de la genceptine pour le traitement des troubles metaboliques
WO2003013579A1 (fr) * 2001-08-03 2003-02-20 Genset S.A. Agonistes et antagonistes de lipergix destines au traitement des troubles metaboliques
WO2003013580A1 (fr) * 2001-08-03 2003-02-20 Genset S.A. Traitement des troubles du metabolisme a l'aide d'agonistes et d'antagonistes xidatine
WO2003013582A1 (fr) * 2001-08-06 2003-02-20 Genset S.A. Agonistes et antagonistes de genoxit destines au traitement des troubles du metabolisme
WO2003013578A1 (fr) * 2001-08-07 2003-02-20 Genset S.A. Traitement des troubles metabolique au moyen d'agonistes et d'antagonistes d'omoxine
WO2003013585A1 (fr) * 2001-08-08 2003-02-20 Genset S.A. Agonistes et antagonistes de la mifaxine convenant au traitement de troubles du metabolisme au moyen
WO2003013584A1 (fr) * 2001-08-09 2003-02-20 Genset S.A. Agonistes et antagonistes xafinix destines a etre utilises dans le traitement des troubles metaboliques
WO2003013604A3 (fr) * 2001-08-09 2003-10-09 Genset Sa Traitement des troubles metaboliques par les agonistes et les antagonistes de migenix
WO2003013583A1 (fr) * 2001-08-10 2003-02-20 Genset S.A. Agonistes et antagonistes de faxigene dans le traitement de troubles metaboliques
WO2003026695A1 (fr) * 2001-09-21 2003-04-03 Genset S.A. Agonistes et antagonistes de cylixine permettant de traiter des troubles du metabolisme
WO2003041730A1 (fr) * 2001-11-16 2003-05-22 Genset S.A. Agonistes et antagonistes de ditacine utilises pour traiter des troubles du metabolisme
WO2003045421A1 (fr) * 2001-11-28 2003-06-05 Genset S.A. Agonistes et antagonistes de ryzn pour le traitement de troubles metaboliques
WO2003045422A1 (fr) * 2001-11-29 2003-06-05 Genset S.A. Agonistes et antagonistes de la prolixine pour le traitement des troubles metaboliques
US7344843B2 (en) 2001-11-29 2008-03-18 Serono Genetics Institute S.A. Agonists and antagonists of prolixin for the treatment of metabolic disorders
WO2003047614A1 (fr) * 2001-12-05 2003-06-12 Genset S.A. Agoniste et antagonistes de redax pour traiter les troubles du metabolisme
WO2003047615A1 (fr) * 2001-12-05 2003-06-12 Genset S.A. Traitement de troubles metaboliques au moyen d'agonistes et d'antagonistes de dexar
WO2003049757A1 (fr) * 2001-12-12 2003-06-19 Genset S.A. Agonistes et antagonistes de glucomin pour le traitement de troubles du metabolisme
WO2003049758A1 (fr) * 2001-12-13 2003-06-19 Genset S.A. Agonistes et antagonistes d'energene pour le traitement de troubles du metabolisme
WO2003049759A1 (fr) * 2001-12-13 2003-06-19 Genset S.A. Agonistes et antagonistes d'oxifan pour le traitement de troubles du metabolisme
WO2003049756A1 (fr) * 2001-12-13 2003-06-19 Genset S.A. Agonistes et antagonistes de glucomine a utiliser dans le traitement de troubles metaboliques
WO2003051386A1 (fr) * 2001-12-14 2003-06-26 Genset S.A. Agonistes et antagonistes de glucoset a utiliser dans le traitement de troubles metaboliques
WO2003055509A1 (fr) * 2001-12-26 2003-07-10 Genset S.A. Agonistes et antagonistes du bromix servant au traitement de troubles metaboliques
WO2003077939A1 (fr) * 2002-03-19 2003-09-25 Genset Sa Traitement de troubles du metabolisme par des agonistes et antagonistes d'un membre (fradj and/or cryptic) de la famille des recepteurs du tnf
US7863243B2 (en) 2003-11-04 2011-01-04 Sankyo Company, Limited Anti-tumor agent

Also Published As

Publication number Publication date
EP1085897A4 (fr) 2003-03-12
EP1085897A1 (fr) 2001-03-28
JP2003527067A (ja) 2003-09-16

Similar Documents

Publication Publication Date Title
EP1085897A1 (fr) Acrp30r1l, homologue de acrp30 (proteine associee a un complement de l'adipocyte 30 kd)
US6358707B1 (en) Human F11 antigen: a novel cell surface receptor involved in platelet aggregation
WO2000010583A1 (fr) Gene humain de l'histone deacetylase hd4
EP1179001A1 (fr) Variante d'epissage de metalloproteinase-5 (mt-mmp5-l) de matrice humaine de type membrane
US6245550B1 (en) Cytokine family member EF-7
EP0866127A2 (fr) HE8AN36, un homologue de récepteur d'hormone stéroide
WO1999064629A1 (fr) Acrp30r2, un homologe d'acrp30 (proteine apparentee au complement de l'adipocyte 30 kd)
WO1999049023A1 (fr) Element 2-21 de la famille des cytokines
US20010049121A1 (en) Cytokine family member, 2-19
WO1999011783A2 (fr) Polypeptides de boite t
EP0911391A2 (fr) Clone HWHHJ20
EP1056846A1 (fr) Polypeptides du type cerebelline-2 et adn codant pour ces polypeptides
US20010009905A1 (en) ACRP30R1: A homolog of ACRP30 (30 kd adipocyte complement-related protein)
WO2000017349A1 (fr) GENE HsgIII HUMAIN
EP0875570A2 (fr) Polypeptides neurodégénératives HHPDZ65
EP1098970A1 (fr) Gene sbpsapl humain presentant une homologie avec la famille des facteurs neurotrophiques prosaposiniques
WO2000061598A2 (fr) Profiline-3 du gene specifique du rein de rat
WO2000034470A1 (fr) Npcbac06: gene humain de l'atpase du reticulum endoplasmique de transition
US20020055476A1 (en) RAMP2a: receptor activity modifying protein-2a
WO2000034328A1 (fr) Tpaaoh04: gene humain sara de la proteine g
WO2000021992A1 (fr) Proteine de liaison humaine fk506 (fkbp)
WO2000058353A1 (fr) Npcahh01: gene humain de la proteine transmembranaire e3-16
EP0897986A2 (fr) Protéinase aspartique 5
WO2000021994A1 (fr) Gene humain ptd011 (tpaahe09)
WO2000047616A1 (fr) Tpaace06: gene ptd016 humain

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): JP

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
ENP Entry into the national phase

Ref country code: JP

Ref document number: 2000 549282

Kind code of ref document: A

Format of ref document f/p: F

WWE Wipo information: entry into national phase

Ref document number: 1999923129

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 1999923129

Country of ref document: EP

WWW Wipo information: withdrawn in national office

Ref document number: 1999923129

Country of ref document: EP

点击 这是indexloc提供的php浏览器服务，不要输入任何密码和下载